核心财务预测 - 华尔街分析师预计安捷伦科技季度每股收益为1.37美元 同比增长3.8% [1] - 预计季度营收达16.6亿美元 同比增长5.1% [1] - 过去30天内分析师未对每股收益预期进行修正 [2] 业务板块收入预测 - 生命科学与诊断市场板块净收入预计为6.3129亿美元 同比下降19.3% [5] - 安捷伦跨实验室集团净收入预计为7.2015亿美元 同比大幅增长75.2% [5] - 制药终端市场收入预计达5.8131亿美元 同比增长7.7% [7] - 化学与先进材料终端市场收入预计为3.7671亿美元 同比增长5.8% [6] - 环境与法医终端市场收入预计为1.707亿美元 同比增长1.6% [6] - 诊断与临床终端市场收入预计为2.498亿美元 同比增长3.2% [7] - 食品终端市场收入预计为1.5033亿美元 同比增长4.4% [8] - 学术与政府终端市场收入预计为1.3761亿美元 同比增长7.5% [7] 市场表现与评级 - 过去一个月公司股价回报率为-2.7% 同期标普500指数上涨1.1% [8] - 公司目前获Zacks评级为3级(持有) 预计未来表现将与整体市场持平 [8]

核心财务预测 - 华尔街分析师预计公司季度每股收益为106美元 同比增长104% [1] - 季度收入预计达107亿美元 同比增长62% [1] - 过去30天内共识EPS预测保持稳定 反映分析师对初始预测的集体重新评估 [1] 细分业务收入预测 - CVI业务收入预计达72397万美元 同比增长72% [4] - CSI业务收入预计达34337万美元 同比增长49% [4] - CSI业务中外科手术部门收入预计20917万美元 同比增长57% [4] - CSI业务中生育部门收入预计13462万美元 同比增长41% [5] - CVI业务中球面及其他产品收入预计371亿美元 同比增长62% [5] - CVI业务中环面及多焦点产品收入预计35282万美元 同比增长81% [6] 区域收入分布 - 美洲地区收入预计31149万美元 同比增长113% [6] - 亚太地区收入预计14368万美元 同比增长31% [6] - EMEA地区收入预计26771万美元 同比增长44% [7] 股价表现与市场对比 - 公司股价过去一个月下跌1% 同期标普500指数上涨11% [7] - 公司Zacks评级为3级(持有) 预计未来表现与整体市场持平 [7]

Analysts on Wall Street project that Keysight (KEYS) will announce quarterly earnings of $1.68 per share in its forthcoming report, representing an increase of 7% year over year. Revenues are projected to reach $1.31 billion, increasing 7.9% from the same quarter last year. The consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timefr ...

Wall Street analysts forecast that Eaton (ETN) will report quarterly earnings of $2.92 per share in its upcoming release, pointing to a year-over-year increase of 7%. It is anticipated that revenues will amount to $6.93 billion, exhibiting an increase of 9.1% compared to the year-ago quarter. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ...

业绩预测 - 华尔街分析师预测Biogen Inc (BIIB)即将公布的季度每股收益为3.94美元 同比下滑25.4% [1] - 预计季度营收为23.2亿美元 同比下降5.8% [1] - 过去30天内 分析师对每股收益的共识预期下调了2.7% [2] 产品收入预测 多发性硬化症(MS)产品线 - TYSABRI总收入预计3.7266亿美元 同比下降19.4% [5] - 美国市场收入预计2.0391亿美元 同比下降18% [6] - 国际市场收入预计1.7191亿美元 同比下降19.5% [6] - Fumarate类产品TECFIDERA收入预测 - 美国市场预计3202万美元 同比下降27.4% [7] - 国际市场预计1.4372亿美元 同比下降30.9% [7] - Interferon类产品收入预测 - 美国市场预计1.2957亿美元 同比下降10.9% [9] - 国际市场预计9429万美元 同比下降10.6% [9] 罕见病产品线 - SPINRAZA总收入预计3.9692亿美元 同比下降7.5% [5] - 美国市场收入预计1.5629亿美元 同比微降0.6% [8] - 国际市场收入预计2.4401亿美元 同比下降10.2% [8] - SKYCLARYS收入预计1.2837亿美元 同比增长28.4% [5] 其他财务指标 - 产品净收入预计17.2亿美元 同比下降9.5% [6] - 过去一个月公司股价下跌1.7% 同期标普500指数上涨3.4% [10] - 目前Zacks评级为3级(持有) 显示其表现可能与整体市场同步 [10]

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short- term price performance of a stock. Analysts on Wall Street project that Snap-On (SNA) will announce quarterly earnings of $4.61 per share in its forthcoming report, representi ...

Analysts on Wall Street project that Hilton Worldwide Holdings Inc. (HLT) will announce quarterly earnings of $1.61 per share in its forthcoming report, representing an increase of 5.2% year over year. Revenues are projected to reach $2.71 billion, increasing 5.2% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections ...